Azax

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azax

Property Description
Active ingredient Azithromycin dihydrate
Form Tablets, capsules, oral suspension, injectable solution
Pharmacological class Macrolide antibiotic (Azalide subclass)
Common use Anti-infective management of bacterial conditions
Origin Semi-synthetic

What Type of Medicine is Azax?

Azax is a prescription antibiotic whose active ingredient is Azithromycin. It is classified as an antimicrobial agent primarily used to control and resolve a wide range of bacterial infections. Azithromycin belongs to the wider macrolide family of antibiotics, but it is specifically known as a semi-synthetic azalide due to a unique modification in its chemical structure. As an antibacterial agent effective against susceptible organisms, the medication works to address certain bacteria responsible for causing illness.


Composition, Origin, and Available Forms

The core substance of Azax is Azithromycin dihydrate, a single-ingredient product formulated with various standard pharmaceutical excipients necessary for stability and delivery. The designation of Azithromycin as a semi-synthetic compound reflects its unique chemical synthesis, which yields advantages over the naturally derived macrolides, such as enhanced acid stability. This medication is available across several high-level dosage forms, including tablets, capsules, and powder for oral suspension, allowing for versatile oral administration to different patient groups. The oral suspension is often specifically recognized for its use in pediatric patients. Formulations also exist as an ophthalmic solution and an injectable solution, which permits intravenous administration in clinical settings, ensuring flexibility in delivery.


How Does Azithromycin Generally Benefit the Patient?

Azithromycin generally benefits the patient by acting as a powerful Protein Production Blocker inside bacterial cells. The drug selectively binds to the bacteria’s internal machinery (ribosomes), effectively stopping them from manufacturing the proteins essential for their growth, survival, and replication. This action is predominantly bacteriostatic, meaning it inhibits the growth of the pathogen. Through the inhibition of bacterial protein synthesis, the medication provides reliable antimicrobial action. By halting the spread and multiplication of the bacteria, Azithromycin reduces the overall infectious burden, providing the patient's natural immune system the necessary time and opportunity to successfully clear the remaining, stationary pathogens.

Regulatory References

  1. National Library of Medicine (NIH)

What side effects are possible with Azax?

Possible Side Effects and Safety Information

Azax (azithromycin) is associated with a range of officially documented side effects, spanning from common gastrointestinal disturbances to rare but serious adverse reactions, as defined in governmental regulatory documents.

Adverse Reactions Overview

Category Common Adverse Reactions Serious Adverse Reactions (Rare)
Gastrointestinal Diarrhea, abdominal pain, nausea, vomiting Clostridioides difficile-Associated Diarrhea (CDAD)
Cardiovascular N/A QT interval prolongation, Torsades de Pointes, cardiovascular death
Hepatic Abnormal liver function tests Hepatic necrosis, cholestatic jaundice, fatal hepatic failure
Immune/Skin N/A Anaphylaxis, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), DRESS

Safety Considerations and Restrictions

Serious and Clinically Significant Risks:

  • Cardiac Risks: Azax can prolong the QT interval, a potential electrical disturbance of the heart that may lead to the serious arrhythmia Torsades de Pointes and cardiovascular death. This risk is elevated in patients with existing proarrhythmic conditions, such as known QT prolongation, low blood potassium or magnesium, and bradyarrhythmias.
  • Hepatotoxicity: Severe, sometimes fatal, hepatic failure has been reported. The drug should be immediately discontinued if signs of hepatitis occur.
  • Hypersensitivity: Severe, life-threatening allergic reactions, including SJS, TEN, and DRESS, have occurred, requiring immediate treatment cessation.
  • Myasthenia Gravis: Use of Azax may cause the exacerbation of muscle weakness in patients with myasthenia gravis.

Population-Specific Warnings:

  • The use of Azax in neonates (up to 42 days old) has been associated with reports of Infantile Hypertrophic Pyloric Stenosis (IHPS).

Restrictions:

  • Azax is contraindicated in patients with a known hypersensitivity to azithromycin, erythromycin, or any macrolide or ketolide drug, and in those with a history of cholestatic jaundice or hepatic dysfunction associated with previous use.

Overdose and Emergency Response

Overdose and When to Seek Help

Azax overdose is officially documented to primarily involve severe gastrointestinal symptoms. These documented clinical manifestations include acute nausea, vomiting, and diarrhea. The most serious outcome associated with overdosage is the potential effect on the cardiovascular system. Official labeling specifies the risk of prolonged cardiac repolarization and subsequent QT interval prolongation. This may lead to a potentially fatal irregular heart rhythm known as Torsades de pointes and acute cardiovascular death.

Because of this severe, documented risk, regulatory guidance mandates that patients seek immediate care if any cardiac-related signs, such as an irregular heartbeat, shortness of breath, dizziness, or fainting, are observed. Emergency services must be called immediately in the event of collapse.

There is no specific antidote for Azithromycin listed in official prescribing information. Therefore, management is restricted to general symptomatic and supportive measures as required, which can include the administration of medicinal charcoal. For neonates (up to 42 days old), severe vomiting or irritability with feeding must be promptly reported to a physician. This structure of documented severe outcomes, mandated action, and supportive care defines the official regulatory profile of Azax overdose.

Therapeutic Uses of Azax

What Azax Treats: Main Uses and Benefits

Azax is commonly used as an antimicrobial agent and provides symptomatic relief across several key therapeutic domains. The medication is relevant in clinical settings marked by increased discomfort or tension caused by susceptible bacterial pathogens. Its use contributes to improved day-to-day comfort during periods of heightened symptoms and is relevant for easing symptoms related to systemic imbalance.

Azax (Azithromycin) is used to treat certain bacterial infections of the ears, lungs, sinuses, skin, throat, and reproductive organs. This medication is commonly applied in conditions involving acute bacterial infections of the respiratory tract, such as community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis. Azax generally helps address symptom clusters that may appear suddenly, like fever, acute cough, and localized pain, and may assist with coping more steadily with symptom fluctuations.

Azax is also relevant for uncomplicated dermal infections and for managing symptom patterns associated with certain sexually transmitted infections (STIs). Furthermore, it is applied in contexts where long-term symptomatic support may be appropriate, such as is applied in addressing the symptomatic burden of opportunistic infections like disseminated Mycobacterium avium complex in vulnerable patients. This broad application supports patients during episodes of heightened discomfort.

"Azax provides supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load during an acute episode."


Quick Fact: Relief for Acute Infection Symptoms

Quick Fact: Azax is relevant for easing symptoms that become more disruptive during flare-ups, especially those related to systemic imbalance, and supports the patient during episodes of heightened discomfort.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for using Azax (Azithromycin) is determined by official regulatory classifications regarding patient history, age, and pre-existing conditions.

Contraindications (Must Not Use)

Azax is contraindicated in patients with a known hypersensitivity to azithromycin, erythromycin, or any macrolide/ketolide drug. It is also prohibited for individuals with a history of cholestatic jaundice or liver dysfunction associated with prior use of azithromycin.

Age and Special Population Rules

Population Group Regulatory Status Constraint
Pediatric Use Not Established Safety/effectiveness are not established for children under 6 months of age.
Neonates (up to 42 days) Specific Warning Use has been associated with reports of Infantile Hypertrophic Pyloric Stenosis (IHPS).
Pneumonia Patients Not Recommended Not recommended for patients with moderate to severe illness, known bacteremia, or risk factors like cystic fibrosis.

Conditional Use and Restrictions

Caution is required for use in patients with pre-existing proarrhythmic conditions, including known QT interval prolongation or uncompensated heart failure. Caution is also advised in patients with Myasthenia Gravis (risk of exacerbation) and those with severe renal or hepatic impairment. Use during pregnancy is conditional; it is recommended only if the benefit is deemed to outweigh the risk, based on official regulatory status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Interaction Profile

Azax (Azithromycin) has documented interaction patterns that require specific precautions or contraindications, as stated in regulatory prescribing information. Co-administration with Ergot alkaloids (e.g., Ergotamine) is generally contraindicated due to the potential for acute ergotism. The combination with other agents known to prolong the QT interval, such as Pimozide and Class IA or Class III antiarrhythmics, is associated with a pharmacodynamic risk of cardiac arrhythmia.

Azithromycin is known to inhibit P-glycoprotein (P-gp), which may increase the systemic exposure of co-administered P-gp substrate medicines like Digoxin and Colchicine, often necessitating close monitoring. When co-administered with oral coumarin-type anticoagulants (e.g., Warfarin), regulatory documents note reports of enhanced effects, potentially resulting in an increased International Normalized Ratio (INR).

Administration Constraints

To ensure proper absorption, Aluminum- or Magnesium-containing Antacids must not be taken simultaneously with Azithromycin. Official timing rules require separation: Azithromycin must be administered at least 1 hour before or 2 hours after the antacid dose. Although Nelfinavir is documented to significantly increase Azithromycin's exposure (AUC), a dose adjustment for Azithromycin is typically not recommended.

Mechanism of Action

Targeted Inhibition of Bacterial Protein Assembly

The drug's primary action is the selective inhibition of protein synthesis within susceptible bacteria. Azithromycin achieves this by physically binding non-covalently to the 50S ribosomal subunit, specifically the 23S ribosomal RNA, thereby blocking the ribosomal exit tunnel. This action interrupts the peptide chain elongation process, which is necessary for bacterial replication and growth, transitioning the bacteria into a state of inhibited growth.


Anti-replicative Cascade and Immune Modulation

This molecular blockade initiates a cascade where the bacteria's growth and spread are restricted. This anti-replicative effect reduces the concentration of replicating bacterial cells. A secondary mechanistic domain involves the drug's accumulation within host immune cells, where it contributes to the modulation of local inflammatory mediators at the site of infection, influencing the host immune system's mechanism for eliminating microbial cells.


Biological Constraints on Mechanistic Efficacy

The effectiveness of this mechanism is constrained by bacterial counter-mechanisms, which include mutations in the ribosomal binding site (preventing attachment) and the activation of efflux pumps (which actively pump the drug out of the cell). These constraints prevent the molecule from achieving the necessary inhibitory concentration at the ribosome, resulting in the unconstrained growth and replication of the bacterial population.

Dosage and Administration Information

Official Administration Routes and Schedules

Azax (azithromycin) is administered via approved routes including oral (tablets, capsules, suspension), intravenous (IV), and topical (ophthalmic solution). The choice of route and dose is strictly determined by the prescribed course.

Standard Labeled Dosing Regimens (Adults)

Official dosing for multi-day therapy often follows a regimen of 500 mg on the first day, followed by 250 mg once daily on Days 2 through 5. Alternative short courses prescribe 500 mg once daily for three consecutive days.

For specific single-dose therapy, the dose is 1 g or 2 g (where approved) taken as a single administration. Long-term use for prophylaxis, such as for Disseminated Mycobacterium avium complex, is typically dosed at 1200 mg once weekly.

Administration Pattern Example Dose/Frequency Duration Pattern
Split-Dose Oral 500 mg Day 1, then 250 mg daily Total 5-day course
Short-Course Oral 500 mg once daily Total 3-day course
Single-Dose Oral 1 g or 2 g One time administration

Administration Conditions and Preparation

  • Food Relation: Tablets and standard oral suspension may be taken with or without food. Capsules or extended-release suspensions must be taken on an empty stomach (e.g., 1 hour before or 2 hours after a meal).
  • Antacids: Co-administration with antacids should be avoided by at least a 2-hour interval.
  • IV Administration: The lyophilized powder must be reconstituted and then further diluted to a specific concentration for infusion. It must not be administered as a rapid bolus or intramuscular injection.

Population-Specific Rules

  • Pediatric Dosing: For children, dosing is primarily weight-based (e.g., 10 mg/kg or 12 mg/kg), and must not exceed the maximum adult dose.
  • Renal/Hepatic Impairment: No dose adjustment is required for patients with mild to moderate impairment.
  • Missed Dose: A missed dose should be taken as soon as it is remembered. The next dose should then be taken at the regularly scheduled time.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Azax (Azithromycin)

Research evidence for Azax (Azithromycin) is based on findings from official sources, including controlled clinical trials (RCTs), comparative studies, and systematic reviews. The focus of this research was studied for its application in specific bacterial conditions and in certain long-term maintenance scenarios. The following summary outlines the types of research available and the outcomes that were monitored in the observed populations.


Evidence for Acute Respiratory and Skin Infections

For Community-Acquired Pneumonia (CAP), large-scale RCTs were conducted comparing Azax with other recognized antibiotic regimens. The primary outcomes research examined were the measurement of symptom change, the monitoring of microbial status of the causative bacteria, and patient survival tracked over intervals. Studies reported measurements observed where Azax was compared with standard treatments. The regulatory landscape emphasizes the need to monitor for increasing microbial resistance, which may affect the use of the medication for this condition.

In the case of Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) and Uncomplicated Skin and Skin Structure Infections (SSSI), short-term trials were observed in adults and children to explore outcomes related to systemic or functional imbalance. For SSSI, the main endpoint was studied for was clinical outcome status, defined by the status of the infection signs and symptoms.


Evidence for Sexually Transmitted and Opportunistic Infections

Research related to Urogenital Chlamydia Trachomatis infection primarily consists of RCTs. The key outcome research examined was status of microbiological outcome, confirmed by laboratory testing. While findings describe patterns observed in the studies for uncomplicated urogenital infections, subgroup findings are uncertain for infections at non-genital sites, where comparative evidence is lacking or findings were mixed against alternative therapies.

For Disseminated Mycobacterium avium Complex (MAC), trials were observed in specific patient groups, mainly those with advanced HIV/AIDS, tracking long-term outcomes such as the diagnosis rate of MAC disease and patient survival. These studies reported on Azax being used as part of a combination regimen.


What the Research Does Not Fully Address

A primary uncertainty across multiple indications is antimicrobial resistance. Studies observed that increased use can contribute to the development of resistant bacteria. Comparative evidence is lacking in some areas when assessing Azax against the newest therapeutic options. Furthermore, there is limited information for long-term outcomes regarding the durability of response across many populations. The results apply only to the populations studied and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Azax (FAQ)


Q: Does Azax need to be taken with food?

A: Official guidance regarding food depends on the specific form of Azax. Official drug labeling states that tablets and standard liquid suspensions may be taken with or without food. However, certain other forms, such as capsules or extended-release suspensions, must be taken on an empty stomach (for example, 1 hour before or 2 hours after a meal).


Q: Are there any major food or drink restrictions while using Azax?

A: The primary administration restriction noted in official labeling involves antacids containing aluminum or magnesium. Official timing rules require separation: Azax must be administered with at least a 2-hour interval between the two doses. Beyond this and the empty stomach requirement for some dosage forms, no other major food or drink restriction is consistently highlighted.


Q: Is Azax an antibiotic or an anti-inflammatory drug?

A: Azax is fundamentally classified as a macrolide antibiotic because its main purpose is to inhibit the growth of susceptible bacteria. However, studies and official information indicate that beyond its primary function, it may also contribute to the modulation of local inflammatory mediators at the site of infection.


Q: What is the function of the active ingredient in Azax?

A: The active ingredient, Azithromycin, works by achieving selective inhibition of protein synthesis inside bacterial cells. It physically binds to the bacterial ribosome, which is the internal machinery needed to manufacture proteins. This action interrupts the process necessary for the bacteria to grow and replicate.


Q: Is Azax generally considered a long-term or short-term treatment?

A: Azax is approved for both short-term courses, such as 1-day single doses or 3- to 5-day regimens for acute infections. Additionally, it is also approved for long-term use in specific prophylactic scenarios, such as the once-weekly dosing for Disseminated Mycobacterium avium complex (MAC) disease.


Q: Is Azax available as a generic medicine?

A: Yes, the active ingredient in Azax, which is Azithromycin, has been established for a long time. It is widely available as a generic medicine from various manufacturers, in addition to being sold under several brand names.


Q: Is Azax safe to use for older adults?

A: Official labeling indicates that caution is necessary for use in older adults. This population may be more susceptible to certain risks, such as the potential for developing Torsades de Pointes arrhythmias, which are electrical disturbances of the heart.


Q: Does Azax interact with contraceptives?

A: Azithromycin may theoretically reduce the effectiveness of some estrogen-containing hormonal contraceptives, though the risk is generally considered low. Some official product information has noted the need for using a backup method of birth control during the course of treatment.


Q: Can Azax be taken with over-the-counter pain relievers?

A: Official labeling does not list common over-the-counter pain relievers, like ibuprofen or acetaminophen, as major drug interactions or contraindications. Regulatory interaction warnings list specific agents such as certain heart rhythm medications, blood thinners, and antacids.


Q: Does Azax interact with grapefruit or grapefruit juice?

A: Official drug labels do not list grapefruit or grapefruit juice as a specific food interaction that requires avoidance or precautionary steps. The primary administration restriction involves the timing of administration related to antacids.


Q: Why are people told not to drink alcohol while taking Azax?

A: Azax’s official regulatory warnings do not list alcohol as a specific drug interaction that is contraindicated. Regulatory documents do not mandate abstinence, but alcohol can potentially worsen reported side effects like nausea.


Q: Does taking Azax require regular blood tests or monitoring?

A: Specific monitoring is required when Azax is co-administered with certain other medicines that Azax can affect. For example, close monitoring of blood levels or coagulation tests (INR) is generally warranted when the drug is used with Digoxin or oral anticoagulants like Warfarin.


Q: What if Azax doesn't seem to be working for me?

A: Official documents caution that the drug’s effectiveness can be constrained by bacterial counter-mechanisms, such as the development of antimicrobial resistance. Resistance can prevent the drug from achieving the necessary inhibitory concentration at the site of action.


Q: Does Azax have a risk of dependence or addiction?

A: Azax (Azithromycin) is not classified as a controlled substance by regulatory agencies and is not associated with the known risks of dependence or addiction typically found with controlled medications.


Q: Is Azax mentioned in clinical practice guidelines?

A: Yes, official drug labeling refers to its role in the context of clinical treatment. It notes that certain regimens, such as its use for Neisseria gonorrhoeae, should be administered according to local clinical treatment guidelines.


Q: What is the maximum duration someone can be on Azax, according to research?

A: Official dosing is typically for short periods, such as 3 or 5 days for acute infections. The longest duration described in official dosing regimens is its once-weekly administration for the prophylaxis of Disseminated Mycobacterium avium complex (MAC) disease, which is a long-term maintenance regimen.


Q: Can I drive or operate machinery while taking Azax?

A: Official documents note there is no clear evidence that Azax affects the ability to drive or operate machinery. However, due to the potential for side effects such as dizziness or blurred vision, general caution is recommended while performing tasks that require full alertness.


Q: Can Azax affect fertility?

A: Regulatory and authoritative information indicates there is no clear evidence to suggest that taking Azax reduces fertility in either men or women.


Q: Is it common to feel nauseous when starting Azax?

A: Nausea is classified in official documents as one of the most common adverse reactions reported with Azax. In clinical trials, this side effect was frequently reported, often during the initial days of treatment.


Q: Why do some people report feeling tired on Azax?

A: Tiredness or fatigue is not among the most common adverse effects, but it has been reported as an uncommon or serious side effect in some post-marketing data. This may be related to the body's response to the drug or, in rare cases, to more severe effects like liver problems.


Q: Is it normal to feel a little dizzy when first taking Azax?

A: Dizziness is listed in official documentation as a known adverse reaction to Azax. While its occurrence is variable, some trial data reports it as common. General caution is described in the label; signs of severe dizziness or fainting are officially listed as conditions requiring immediate attention.


Q: Can Azax cause mood changes or anxiety?

A: Adverse events related to mood are reported, though uncommonly. Official documents list side effects suchs as nervousness (uncommon) and agitation (rare). Other reactions like hostility or depression have been reported where the precise incidence is not exactly known.


Q: Does Azax cause weight changes?

A: Weight changes are not listed among the most common adverse reactions reported in clinical trials. Some reports describe 'rapid weight gain' or 'unusual weight loss' in postmarketing data, but these reactions are rare, and their incidence cannot be reliably estimated.

How should Azax be stored and disposed of?

How to Store and Dispose of Azax (Azithromycin)

Azithromycin products, including tablets and the dry powder, must be stored at controlled room temperature (20 C to 25 C). The medicine must be kept in a closed container, protected from excessive heat, moisture, and freezing. All forms should be stored securely and kept out of the reach of children.

Stability and Disposal

The standard liquid suspension is stable for 10 days after mixing, and the extended-release suspension is only stable for 12 hours. Any unused portion must be discarded after these periods. For disposal of expired or unused medicine, regulatory guidance recommends using a drug take-back program. If a program is unavailable, tablets or capsules should be mixed with an unappealing substance, placed in a sealed bag, and thrown in the trash. The medicine must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azax found in:

A-Z Index: